Ibogaine cardiac safety concerns will materially slow or condition U.S. regulatory pathways, requiring mandatory cardiac monitoring protocols that will significantly increase deployment costs and complexity

The convergence of three independent ibogaine cardiac papers in a single 48-hour window — covering QT prolongation, ventricular arrhythmia risk, and unrecognized OUD comorbidity — constitutes precisely the kind of clustered safety signal that triggers FDA Risk Evaluation and Mitigation Strategy (REMS) requirements. Historical precedent is instructive: the FDA's 2019 REMS for esketamine (Spravato) mandated in-clinic administration and post-dose monitoring for 2 hours, adding ~$300-500 per patient session in facility overhead. Ibogaine's cardiac liability is substantially more acute than esketamine's dissociation risk — QT prolongation and arrhythmia require continuous ECG monitoring, cardiologist sign-off protocols, and crash-cart readiness that most addiction treatment facilities cannot absorb. The 5-to-2 agent consensus here is significant. The two dissenters (veterans_advocate and maps